ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer.

Cancer Res Treat · 2017 · PMC5512356 · PMID 27737534

Europe PMC DOI

hedged sentence

0.0850

closest p · 1.7× alpha

0.0850

boldest claim

The sentences

showed a trendp=0.085so close (0.05 < p ≤ 0.1)

Additionally, the GP arm showed a trend toward a higher RR than the IP arm in the ERCC1-negative group (32.6% vs. 21.6%, respectively; p=0.085).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.